viewLancor Scientific

Tumour Trace: A revolution in cancer detection

Here we look at an emerging medical technology that has come up with a scientific breakthrough that transforms the way we pick up the tell-tale signs of the killer disease

The device is cancer agnostic

Nottingham-based Tumour Trace has developed the OMIS cancer detection system.

OMIS stands for Opto-magnetic Imaging Spectroscopy and it was the brainchild of Professor Djuro Koruga, the company’s chief scientific officer.

It is the physical embodiment of his research at the University of Belgrade and, put simply, the device detects the minute electromagnetic changes that occur in tissue as cancer emerges and develops.

A sample can be garnered using minimally invasive techniques and read-outs emerge in ‘near’ real-time (less than 30 seconds), while the technology itself is “cancer agnostic”. That said, it is currently CE marked as a screening tool for cervical cancer.

READ: The our big picture overview of Lancor Scientific

WATCH: A tangible solution for cancer screening

Be aware there is a difference between a screening device and a diagnostic.

Screening is a pre-emptive process that sees tens of thousands of people annually assessed for the early signs of breast, cervical and prostate cancers.

It saves many lives but it isn’t an exact science, with around a 60% strike rate. In other words, there are a lot of false positives.

OMIS is a far more reliable predictor. Its sensitivity is 84% and its specificity is 77%. That puts it right at the top end for screening.

READ: Blockchain is the Swiss Army knife of the information era

However, for it to be a proper diagnostic tool it needs to rival the gold standard in this arena – biopsy. So, the aim is to refine OMIS to the point where it provides the correct diagnosis around 97% of the time.

Clinical trials of the technology are set to take place in Germany, Austria and the UK, alongside retrospective analysis.

OMIS may struggle (initially at least) to supplant the current techniques used in the developed world, which is why the early adopters are likely to be in the emerging countries where screening is non-existent.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lancor Scientific named herein, including the promotion by the Company of Lancor Scientific in any Content on the Site, the Company receives...


2 min read